Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis
Authors' conclusion
In a real-world setting, baseline PINP value was associated with the increased BMD of TH and FN by ROMO treatment in treatment-naive patients.
Study context
- Population
- Patients with treatment-naive postmenopausal osteoporosis treated with romosozumab for 12 months (mean age 72.6 years; mean baseline PINP 68.5 µg/L)
- Participants
- 63 patients
- Outcome
- Factors associated with clinically significant increased BMD (≥ 3%) in both TH and FN
- Follow-up
- 12 months
Methodological detailsmulticenter, real-world setting
- Multicenter
- Real-world setting
Main finding
As reported in the abstract
Baseline PINP and ≥ 3% increased BMD in both TH and FN (multiple regression)
- Only baseline PINP was significantly and independently associated with ≥ 3% increased bone mineral density (BMD) in both TH and FN; 95% CI
- 1.006-1.054
- P value
- p = 0.019
- Optimal PINP cut-off
- 53.7 µg/L
- Sensitivity of PINP cut-off
- 54.3%
- Specificity of PINP cut-off
- 92.3%
- AUC of PINP
- 0.752
Observational data: associations, not effects.
Further findings
Percentage change of BMD from baseline · 12 months
- LS
- 17.5%
- TH
- 4.9%
- FN
- 4.3%
Responder analysis · 12 months
- Achieved ≥ 6% increased LS-BMD
- 96.8%
- Could not achieve ≥ 3% increased BMD in either TH or FN
- 57.1%
Original publication
Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int. Published 31 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →